Novel strain and application thereof

Abstract

The invention relates to a novel bacterial strain and application thereof. The bacterial strain is saccharomyces cerevisiae KCTC14779BP; the invention also relates to a preparation method of a fermentation product and a preparation method of a fraction comprising the polypeptide. And a cosmetic composition, a foreign medicine composition, or a food composition comprising at least one substance selected from the group consisting of the strain, a culture of the strain, a fermented product of the strain, and a fraction of the culture or the fermented product. A strain of Saccharomyces cerevisiae, Lactobacillus fructovorans, Bacillus paramycosis, or Bacillus megaterium, a culture of the strain, a fermented product of the strain, or a culture or a fraction of the fermented product has excellent effects of improving skin and calming sensitive skin. Therefore, the use ratio of the composition as a skin-improving cosmetic composition, a pharmaceutical composition, and a food composition is high. Therefore, various industrial applications such as cosmetics, foreign drugs and food can be expected.

Description

[0001] This application is a divisional application of the original invention patent application with application number 202280017957.X (International application number: PCT / KR2022 / 020240, application date: December 13, 2022, invention name: New strains and their uses). Technical Field

[0002] The present invention relates to a strain selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructivorans KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP; and a cosmetic composition, quasi-drug composition, or food composition comprising any one or more selected from the group consisting of the above strains, cultures of the above strains, fermentations of the above strains, and fractions of the cultures or fermentations. Background Art

[0003] Cosmetic ingredients are known to cause skin problems such as inflammation, acne, and swelling (Maibach HI, Contact Dermatitis, 6, 369-404, 1980). Furthermore, many substances used as ingredients in functional cosmetics have problems with low skin stability or insignificant effects.

[0004] For example, cosmetics known for improving skin wrinkles and elasticity include retinoids, adenosine, proteins derived from animal placenta, and chlorella extract. The most widely known retinol has usage limits due to safety concerns such as irritation when applied to the skin. Chlorella extract, for example, has limited effectiveness, so it's difficult to realistically expect it to enhance skin elasticity and improve wrinkles.

[0005] On the other hand, inflammation occurs when cells or tissues are damaged for some reason. This occurs as a series of defensive measures aimed at minimizing their reactions and restoring the damaged area to its original state. This triggers reactions in nerves, blood vessels, lymphatic vessels, humoral responses, and cells, ultimately causing pain, swelling, redness, fever, and other symptoms, leading to functional impairments. Inflammation can be caused by physical factors such as trauma, frostbite, burns, and radiation, chemical factors such as acids, and immunological factors such as antibody reactions. In addition, inflammation can be caused by vascular or hormonal imbalances. Various chemical mediators secreted by cells damaged by external stimuli cause vasodilation, and as permeability increases, antibodies, complement, plasma, and phagocytes flock to the inflamed area. This phenomenon contributes to erythema.

[0006] Anti-inflammatory agents are those that eliminate inflammation by removing the source of inflammation and reducing biological reactions and symptoms. Currently, non-steroidal anti-inflammatory agents include flufenamic acid, ibuprofen, benzydamine, and indomethacin, and steroidal prednisolone and dexamethasone. However, most of these agents have issues with skin safety or stability when incorporated into cosmetics, limiting their use.

[0007] Generally speaking, moisturizing cosmetic compositions for skin use retain a certain amount of moisture in human hair and skin, making them appear soft and vibrant while also preventing damage such as cracking and dryness. Specifically, moisturizing cosmetic compositions for skin are used to beautify and maintain the health of skin and hair by supplying or retaining a certain amount of moisture to the skin and hair.

[0008] Therefore, recently, a lot of research has been conducted on cosmetic compositions having excellent skin soothing, regeneration, moisturizing, anti-oxidation or anti-inflammatory effects and excellent effects in improving skin conditions (wrinkles, elasticity, etc.) or preventing skin aging or skin damage. Summary of the Invention

[0009] Technical issues

[0010] The present inventors have conducted research on natural resources for safer raw materials with excellent skin-improving effects, and have confirmed that a novel strain has skin-improving effects. This novel strain is also significantly more effective than existing yeast, Lactobacillus, and Bacillus fermentations, thereby completing the present invention.

[0011] Problem Solving Methods

[0012] One object of the present invention is to provide a strain selected from the group consisting of Saccharomyces cerevisiae deposited with the deposit number KCTC14779BP, Saccharomyces cerevisiae deposited with the deposit number KCTC14780BP, Lactobacillus fructivorans deposited with the deposit number KCTC14776BP, Bacillus paramycoides deposited with the deposit number KCTC14777BP and Bacillus megaterium deposited with the deposit number KCTC14778BP.

[0013] Another object of the present invention is to provide a skin-improving cosmetic composition comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the culture or fermentation product.

[0014] Another object of the present invention is to provide a quasi-drug composition for improving skin, comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the aforementioned culture or fermentation product.

[0015] Another object of the present invention is to provide a skin-improving food composition comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the aforementioned culture or fermentation product.

[0016] Another object of the present invention is to provide a method for preparing a fermented product, comprising the step of fermenting using a strain selected from the group consisting of Saccharomyces cerevisiae deposited with the deposition number KCTC14779BP, Saccharomyces cerevisiae deposited with the deposition number KCTC14780BP, Lactobacillus fructivorans deposited with the deposition number KCTC14776BP, Bacillus paramycoides deposited with the deposition number KCTC14777BP, and Bacillus megaterium deposited with the deposition number KCTC14778BP.

[0017] Another object of the present invention is to provide a fraction preparation method, comprising: a step of culturing a Saccharomyces cerevisiae strain deposited with the deposit number KCTC14780BP; and a step of separating from the culture or fermentation product of the strain using water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane.

[0018] Effects of the Invention

[0019] The yeast cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, or Bacillus megaterium strains of the present invention, cultures thereof, fermented products thereof, fermented products thereof, or fractions thereof have excellent skin-improving effects and are therefore highly useful as skin-improving cosmetic compositions, quasi-drug compositions, and food compositions. Therefore, various industrial applications such as cosmetics, quasi-drugs, and foods are anticipated. DETAILED DESCRIPTION

[0020] Hereinafter, the present invention will be described in detail. Furthermore, the description and embodiments of one aspect disclosed in the present invention may also be applied to the description and embodiments of other aspects for common matters. Furthermore, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Furthermore, the scope of the present invention is not intended to be limited by the detailed descriptions below.

[0021] One aspect of the present invention provides a strain selected from the group consisting of Saccharomyces cerevisiae deposited with the deposit number KCTC14779BP, Saccharomyces cerevisiae deposited with the deposit number KCTC14780BP, Lactobacillus fructosus deposited with the deposit number KCTC14776BP, Bacillus paramycoides deposited with the deposit number KCTC14777BP and Bacillus megaterium deposited with the deposit number KCTC14778BP.

[0022] The term "Saccharomyces cerevisiae" of the present invention refers to a type of yeast belonging to the Saccharomycetaceae family and the genus Saccharomyces. This species has played an important role in winemaking, baking, and brewing since ancient times and has been widely used. For Saccharomyces cerevisiae, the characteristics may change depending on the growing area and natural environmental conditions, and thus the activity of the strain and its fermentation product may change. The Saccharomyces cerevisiae of the present invention can be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Saccharomyces cerevisiae strain may be a strain preserved as KCTC14779BP or KCTC14780BP, but is not limited thereto.

[0023] The term "Lactobacillus fructivorans" in the present invention is a positive bacterium and refers to a type of Lactobacillus (lactic acid bacteria) belonging to the genus Fructilactobacillus. This species is found in wine, beer, grape juice (must), dairy products, cabbage pickled with salt, meat and fish. For Lactobacillus fructivorans, the characteristics will change depending on the growth area and natural environmental conditions, and thus the activity of the strain and its fermentation product may change. The Lactobacillus fructivorans of the present invention can be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Lactobacillus fructivorans strain can be a strain preserved as KCTC14776BP, but is not limited thereto.

[0024] The term "Bacillus paramycoides" in the present invention refers to a species of Bacillus belonging to the Firmicutes order. The characteristics of Bacillus paramycoides vary depending on the region of growth and natural environmental conditions, and thus the activity of the strain and its fermentation product may vary. The Bacillus paramycoides of the present invention can be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Bacillus paramycoides can be a strain deposited as KCTC14777BP, but is not limited thereto.

[0025] The term "Bacillus megaterium (Bacillus subtilis, Priestiamegaterium)" in the present invention is a rod-shaped Gram-positive, aerobic spore-forming bacterium mainly found in a variety of habitats. It refers to a type of Bacillus belonging to the Bacillus family and the Priestia genus. It is widely used as a feed additive for poultry, livestock, aquatic animals, ruminants, etc. For Bacillus megaterium, the characteristics will change depending on the growth area and natural environmental conditions, so that the activity of the strain and its fermentation product may change. The Bacillus megaterium of the present invention can be derived from a fermentation broth, but is not limited thereto. Specifically, in the present invention, the Bacillus megaterium strain can be a strain preserved as KCTC14778BP, but is not limited thereto.

[0026] In the present invention, the fermentation broth can be prepared by fermenting for 6 months to 2 years, specifically 9 months to 1 year and 6 months, more specifically 1 year, and the fermentation broth can be plant fermentation broth, but is not limited thereto.

[0027] In one specific example of the present invention, a fermentation liquid was prepared, and it was confirmed that the fermentation product of Saccharomyces cerevisiae, Lactobacillus fructosus, Bacillus paramycoides or Bacillus megaterium of the present invention had an excellent skin improvement effect compared with the fermentation product of common yeast, namely Saccharomyces cerevisiae, common lactobacillus, namely Lactobacillus fructosus, common bacillus, namely Bacillus paramycoides or Bacillus megaterium.

[0028] Another aspect of the present invention provides a skin-improving cosmetic composition comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the culture or fermentation product.

[0029] The term "strain" in the present invention refers to a collection of individuals derived from a single cell and having homogeneous genetic characteristics through asexual reproduction. Within a species, there are multiple strains with different genetic characteristics. In the present invention, the strain refers to Saccharomyces cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, or Bacillus megaterium, and specifically can be one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778BP, but is not limited thereto.

[0030] In the present invention, the bacterial strains may include cells, dried cells, or crushed products of Saccharomyces cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, or Bacillus megaterium. In this case, the dried cells may be spray-dried, freeze-dried, vacuum-dried, drum-dried, or the like, and the crushed products may be products obtained by chemically or physically crushing the cell walls of the strains themselves.

[0031] The "culture" of the present invention refers to a product obtained by culturing the aforementioned strain in a culture medium. For example, the culture of the present invention may include components remaining in the culture medium after harvesting the culture medium of one or more strains selected from the group consisting of Saccharomyces cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, and Bacillus megaterium, or components of the culture medium containing the strain.

[0032] The culture may be the entire culture, culture supernatant, disrupted product, or fractions thereof of the aforementioned Saccharomyces cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, and / or Bacillus megaterium strains. In this case, the culture supernatant can be obtained by centrifuging the culture of the aforementioned strain, the disrupted product can be obtained by subjecting the aforementioned strain to physical or ultrasonic treatment, and the fractions can be obtained by subjecting the culture, culture supernatant, disrupted product, etc., to centrifugation, chromatography, or the like.

[0033] The culture medium and other culture conditions used in the cultivation of the strain of the present invention can be arbitrarily used without particular limitation, as long as it is a culture medium used for the cultivation of conventional microorganisms of the genus Saccharomyces, Lactobacillus and / or Bacillus. Specifically, the strain of the present invention can be cultured in a conventional culture medium containing an appropriate carbon source, nitrogen source, phosphorus source, inorganic compound, amino acid and / or vitamin, etc., under aerobic or anaerobic conditions while adjusting the temperature, pH, etc.

[0034] In the present invention, the carbon source may include carbohydrates such as glucose, fructose, sucrose, and maltose; sugar alcohols such as mannitol and sorbitol; organic acids such as pyruvic acid, lactic acid, and citric acid; and amino acids such as glutamic acid, methionine, and lysine, but is not limited thereto. Furthermore, natural organic nutrient sources such as starch hydrolysates, molasses, blackstrap molasses, rice bran, cassava, bagasse, and corn steep liquor may be used. Carbohydrates such as glucose and sterilized pretreated molasses (i.e., molasses converted to reducing sugars) may also be used. Other suitable carbon sources may be utilized in various amounts without limitation. These carbon sources may be used alone or in combination of two or more.

[0035] As the nitrogen source, inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate, and ammonium nitrate; and organic nitrogen sources such as amino acids, peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or its decomposition products, defatted soybean cake or its decomposition products can be used. These nitrogen sources can be used alone or in combination of two or more, but are not limited thereto.

[0036] As the phosphorus source, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, or corresponding sodium salts, etc. As the inorganic compound, sodium chloride, calcium chloride, ferric chloride, magnesium sulfate, ferric sulfate, manganese sulfate, calcium carbonate, etc. can be used.

[0037] In addition, the culture medium may include amino acids, vitamins, and / or appropriate precursors. Specifically, L-amino acids may be added to the culture medium of the strain. Specifically, glycine, glutamate, and / or cysteine ​​may be added. L-amino acids such as lysine may be further added as needed, but are not necessarily limited thereto.

[0038] The above-mentioned culture medium or precursor may be added to the culture in a batch manner or a continuous manner, and is not limited thereto.

[0039] In the present invention, during the cultivation of the strain, the pH of the culture can be adjusted by adding compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. to the culture in an appropriate manner. In addition, during the cultivation, bubble generation can be suppressed by using defoamers such as fatty acid polyethylene glycol esters. In addition, oxygen or oxygen-containing gas can be injected into the culture to maintain the aerobic state of the culture, or no gas can be injected or nitrogen, hydrogen or carbon dioxide gas can be injected to maintain anaerobic and microaerobic states.

[0040] The culture temperature may be 25 to 40° C., more specifically 28 to 37° C., but not limited thereto. The culture may be continued until the desired amount of useful substances is produced, specifically 1 to 200 hours, but not limited thereto.

[0041] For the purposes of this invention, the term "fermentation" refers to the process by which microorganisms decompose organic matter using their own enzymes, which is not part of the putrefaction process. Fermentation and putrefaction reactions proceed through similar processes, but the decomposition process is considered fermentation if it produces useful substances, while putrefaction is considered putrefaction if it produces malodorous or harmful substances.

[0042] In the present invention, the method for obtaining a fermentation product from the above-mentioned strain is not particularly limited. The fermentation product can be obtained by inoculating the strain into a culture medium and culturing the culture at 20°C to 40°C with shaking for 1 to 200 hours, isolating the cells by centrifugation, and then disrupting the cells by ultrasonic treatment. Alternatively, the fermentation product can be obtained according to methods commonly used in the art or similar fields.

[0043] In the present invention, there is no limitation on the type of culture medium for inoculating the strain, as long as the strain can ferment.

[0044] In the present invention, the fermentation product obtained from the above-mentioned strain includes not only the fermented substance itself, but also all kinds of substances including the fermentation product produced by the above-mentioned strain, for example, the culture medium of the strain in which the strain and the culture coexist, the fermentation product of the strain filtered from the above-mentioned culture medium, the fermentation product obtained by sterilizing the strain from the above-mentioned culture medium and filtering it, the extract of the above-mentioned fermentation product or the culture medium containing it, the dilution solution of the above-mentioned fermentation product or its extract, the dried product of the above-mentioned fermentation product or its extract, the lysate of the bacterial body of the above-mentioned strain collected and crushed, etc.

[0045] The term "fraction" in the present invention refers to a product obtained by a fractionation method of separating a specific component or a specific group from a mixture containing a plurality of constituent components.

[0046] In the present invention, the fractionation method for obtaining the above-mentioned fractions is not particularly limited and can be performed according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, a method of obtaining fractions from the above-mentioned extract by treating an extract obtained from a culture or fermentation product of an extraction strain with a predetermined solvent can be cited.

[0047] In the present invention, the type of solvent used to obtain the above-mentioned fractions is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the above-mentioned fractionation solvent include polar solvents such as water and alcohol; and non-polar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane. These can be used alone or in combination of two or more. When an alcohol is used as the above-mentioned fractionation solvent, a C1 to C4 alcohol can be preferably used.

[0048] In the present invention, the fraction may include polypeptides extracted from a culture or fermentation product of a strain.

[0049] In the present invention, a peptide refers to a polymer of amino acid monomers artificially or spontaneously linked, a substance composed of two or more amino acids, and is referred to as a tripeptide, oligopeptide, or polypeptide depending on the number of amino acids. Specifically, in the present invention, a polypeptide may refer to a polypeptide comprising more than 100 amino acids, but is not limited thereto.

[0050] In the present invention, "polypeptides extracted from a culture or fermentation product of a strain" refers to obtaining a culture or fermentation product from a strain and then isolating a functional peptide aggregate or polypeptide of a certain size or larger within the culture or fermentation product. In the present invention, "polypeptides extracted from a culture or fermentation product of a strain" is used interchangeably with "yeast polypeptides" or "fractions."

[0051] In the present invention, the method for separating fractions from the fermented product is not particularly limited, but the fractions can be obtained by concentrating and precipitating the lysate of the bacterial cells obtained by fermentation using and disrupting the strain, filtering only the supernatant, and then spray drying.

[0052] The term "skin improvement" in the present invention may be any one or more selected from the group consisting of moisturizing the skin, improving wrinkles, improving elasticity, preventing aging, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, anti-oxidation, anti-aging, protecting the skin from external stimuli, calming sensitive skin, improving sensitive skin, relieving erythema, relieving pruritus, strengthening the skin barrier function and relieving skin irritation, but is not limited thereto.

[0053] The term "improvement" in the present invention refers to all actions that at least reduce parameters related to the relief or treatment of a condition, such as the degree of symptoms, and may fully include any one or more of moisturizing the skin, improving wrinkles, improving elasticity, preventing aging, calming the skin, regenerating the skin, improving skin inflammation and whitening the skin, anti-oxidation, anti-aging, protecting the skin from external stimuli, calming sensitive skin, improving sensitive skin, relieving erythema, relieving pruritus, strengthening the skin barrier function, relieving skin irritation and relieving skin pain.

[0054] The above-mentioned skin improvement can be achieved by promoting hyaluronic acid production, promoting collagen synthesis, enhancing cell activity, inhibiting NO production, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 (prostaglandin E2) expression, increasing LOR (Loricrin) expression, inhibiting TNF-a expression or inhibiting TRPV1 activity, but is not limited to these.

[0055] Specifically, the present inventors have confirmed that the fermentation product of Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide, the fermentation product of Lactobacillus fructosus KCTC14776BP, the fermentation product of Bacillus paramycoides KCTC14777BP, and the fermentation product of Bacillus megaterium KCTC14778BP of the present invention have excellent skin improvement effects compared with the fermentation products of ordinary yeast, ordinary lactobacillus, and ordinary Bacillus. More specifically, it was confirmed that the fermentation product of Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide, the fermentation product of Lactobacillus fructose KCTC14776BP, the fermentation product of Bacillus paramycoides KCTC14777BP or the fermentation product of Bacillus megaterium KCTC14778BP of the present invention have excellent effects of enhancing collagen synthesis, enhancing hyaluronic acid synthesis, enhancing cell activity, inhibiting NO production, inhibiting melanin expression, scavenging free radicals, inhibiting PGE2 expression, increasing LOR expression, inhibiting TNF-a expression or inhibiting TRPV1 activity, etc.

[0056] Therefore, it was confirmed that the yeast of cerevisiae, Lactobacillus fructosus, Bacillus paramycoides, Bacillus megaterium, fermented products thereof and / or fractions of the fermented products of the present invention have excellent skin-improving effects such as improving wrinkles, improving elasticity, preventing aging, moisturizing the skin, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, anti-oxidation, anti-aging, protecting the skin from external irritation, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus, strengthening the skin barrier function, alleviating skin irritation and alleviating skin pain, compared with ordinary yeast, ordinary lactobacillus, ordinary bacillus or their fermented products.

[0057] The term "wrinkles" used in this invention can be broadly categorized as expression wrinkles caused by the facial muscles used for facial expression and fine lines resulting from global or local skin aging. Specifically, wrinkles can be induced by genetic factors, a decrease in collagen and elastic fibers in the dermis, and the external environment. For the purposes of this invention, the term "wrinkles" encompasses all expression wrinkles and fine lines, and is not limited thereto.

[0058] The term "elasticity" of the present invention refers to the force that keeps the skin taut when pressed with fingers, and "improving elasticity" or "enhancing elasticity" means improving the elasticity of the skin by strengthening the structure of the subcutaneous fat layer of an individual, and may refer to improving the elasticity of the skin by utilizing the composition of the present invention.

[0059] The term "aging" in the present invention refers to the phenomenon of the decline of the structure and function of an organism over time. The present invention's prevention of aging is not limited to the degree of aging, as long as aging is improved (e.g., prevented, inhibited, or delayed). In the present invention, wrinkle improvement and aging prevention may be due to, but are not limited to, the promotion of collagen synthesis.

[0060] As used herein, "collagen" refers to a fibrous protein found in most animals, particularly mammals, making up the majority of all connective tissues in the body, including skin and cartilage. Fibroblasts, the most common cells in the body, produce and secrete collagen. Gelatin, widely used in cooking, food, and the pharmaceutical industry, is produced by the irreversible hydrolysis of collagen. A decrease in collagen is a primary cause of wrinkles and reduced skin elasticity, so collagen synthesis is crucial for wrinkle improvement and elasticity enhancement.

[0061] In one specific example of the present invention, it was confirmed that the yeast of the present invention, i.e., Saccharomyces cerevisiae KCTC14779BP fermentation product, Saccharomyces cerevisiae KCTC14780BP fermentation product and / or yeast polypeptide, Lactobacillus, i.e., Lactobacillus fructose KCTC14776BP fermentation product, or Bacillus, i.e., Bacillus paramycoides KCTC14777BP fermentation product, had excellent collagen synthesis enhancement rates, thereby confirming the significant effects of the yeast fermentation product, yeast polypeptide, Lactobacillus fermentation product, or Bacillus fermentation product of the present invention on improving skin wrinkles, enhancing elasticity, etc. (Tables 3, 4, 5, 6).

[0062] The term "moisturizing skin" as used herein refers to all actions that maintain skin suppleness by supplying moisture to the skin or blocking moisture evaporation, and maintain a smooth surface by inducing uniform exfoliation of the skin. "Dry" refers to a state of insufficient skin moisturization. Moisturizing the skin can help improve wrinkles and increase skin elasticity. Specifically, moisturizing the skin may be due to, but is not limited to, promoting hyaluronic acid production.

[0063] The term "hyaluronic acid," as used herein, is a type of glycosaminoglycan, referring to a high-molecular-weight polysaccharide composed of repeating chains of glucuronic acid and N-acetylglucosamine residues. Hyaluronic acid can contain 300 to 1000 times its weight in water, thus binding to water and exerting a moisturizing effect on the skin.

[0064] In one specific example of the present invention, it was confirmed that the yeast of the present invention, namely Saccharomyces cerevisiae KCTC14779BP fermentation product, Saccharomyces cerevisiae KCTC14780BP fermentation product, Lactobacillus, namely Lactobacillus fructose KCTC14776BP, Bacillus, namely Bacillus paramycoides KCTC14777BP fermentation product or Bacillus megaterium KCTC14778BP fermentation product, had excellent hyaluronic acid synthesis enhancement rate, thereby confirming the significant effects of the yeast fermentation product, yeast polypeptide or Bacillus fermentation product of the present invention on preventing aging, moisturizing the skin, etc. (Tables 7, 8, 9, 10, 11).

[0065] The term "regeneration" in the present invention refers to inhibiting the decline in the function of cells, tissues or organs or restoring the declined function. The decline in the function of cells, tissues or organs may be due to damage to the cells, tissues or organs. Such damage may be caused by various factors such as radiation therapy, drug therapy, surgery, infection, inflammation, degenerative diseases, autoimmune diseases, aging, etc. On the other hand, the above-mentioned regeneration can be achieved by promoting cell differentiation, but is not limited to this. "Regenerated skin" in the present invention refers to the repair of damaged parts of skin tissue. In the present invention, regenerated skin may be due to enhanced cell activity, but is not limited to this.

[0066] In one embodiment of the present invention, it was confirmed that there was no effect on cell activity in ordinary yeast fermentation products, while the cell activity rate was significantly high in the yeast of the present invention, namely, Saccharomyces cerevisiae KCTC14780BP fermentation product and / or yeast polypeptide (Table 12).

[0067] The term "skin calming" in the present invention refers to relieving and calming redness, itching, irritation of the skin or sensitive areas, and may include relieving skin irritation. Examples include, but are not limited to, relieving pruritus, relieving skin pain, reducing skin moisture loss, and / or reducing redness.

[0068] The term "inflammation" as used herein refers to an in vivo response to damage or infection of specific tissues, primarily mediated by immune cells. The purpose of this inflammation is to minimize tissue damage, eliminate infected agents, and regenerate tissue. In the present invention, calming and regenerating the skin may be achieved by inhibiting NO production, but is not limited thereto.

[0069] The term "nitric oxide" (NO) in this context has various functions, including removing bacteria and tumors, regulating blood pressure, and mediating neurotransmission. However, if an inflammatory reaction occurs, the expression of iNOS (inducible nitric oxide synthase) in the relevant cells increases, generating large amounts of NO. Excessive NO production can induce tissue damage, gene mutations, nerve damage, and increase vascular permeability, promoting inflammatory reactions such as edema. NO production increases in cells that induce inflammation, while NO production is suppressed when the skin is calm, thus creating a necessary correlation between the two.

[0070] In one specific example of the present invention, it was confirmed that the NO production inhibition ability of the yeast of the present invention, i.e., the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide or Lactobacillus, i.e., Lactobacillus fructose KCTC14776BP, was also better than that of ordinary yeast or Lactobacillus fermentation products, thereby confirming that the yeast of the present invention, i.e., the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide or Lactobacillus, i.e., Lactobacillus fructose KCTC14776BP, had the effect of calming the skin and improving inflammation (Tables 13 and 14).

[0071] In the present invention, the term "whitening" includes methods for increasing the brightness of skin that has lost brightness due to excess pigments such as melanin, or for maintaining skin brightness at a certain level, as well as skin with increased brightness achieved by such methods. Specifically, it refers to whitened skin. "Whitening" can be understood as inhibiting tyrosinase activity, thereby inhibiting melanin production and improving symptoms caused by increased melanin, such as dark spots and freckles.

[0072] In one embodiment of the present invention, when the yeast Saccharomyces cerevisiae KCTC14780BP fermentation product and / or yeast polypeptide of the present invention was treated, the melanin production inhibition rate was excellent, thereby confirming a skin whitening effect (Table 15).

[0073] In the present invention, the term "antioxidant" encompasses all actions that inhibit oxidation, specifically, but not limited to, the removal of free radicals such as reactive oxygen species. Reactive oxygen species oxidize and damage cells in the body, exposing them to various diseases. Furthermore, the skin has a complex antioxidant defense network that protects against reactive oxygen species, thus contributing to its ability to protect the skin from external stimuli.

[0074] The term "anti-aging" in the present invention refers to inhibiting or alleviating the progression of aging. Cellular aging refers to cellular oxidation, and maintaining active oxygen appropriately can be considered the main principle for preventing cellular oxidation and cellular aging.

[0075] In one embodiment of the present invention, when the yeast of the present invention, namely, the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide was treated, the effect of scavenging free radicals (active oxygen species) was excellent, thereby confirming the effects of anti-oxidation, anti-aging and protecting the skin from external stimuli (Table 16).

[0076] The term "sensitive skin" in this application refers to skin that is more sensitive than normal skin to external irritants, allergens, environmental changes, or internal body factors, resulting in irritation reactions or dermatitis. This refers to skin reactions such as erythema (redness), keratinization, and blisters, as well as subjective symptoms such as itching, stinging, irritation, pain, and burning, caused by external irritants such as cosmetics and internal body factors such as hormonal changes.

[0077] In one embodiment of the present invention, when the yeast of the present invention, namely the fermentation product of Saccharomyces cerevisiae KCTC14780BP and / or yeast polypeptide is treated, the expression of erythema / itch inducing factor (PGE2), the expression of LOR (Loricrin), the main component of the skin barrier, the expression of inflammatory cytokines (TNF-a), and the activity of skin neurotropic stimuli inducing factor (TRPV1) are inhibited, which confirms that it has the effect of calming and / or improving sensitive skin by alleviating the representative phenomena of erythema / itch, irritation / pain occurring in sensitive skin and strengthening the skin barrier (Tables 17, 18, 19, 20).

[0078] The term "cosmetic composition" of the present invention can be a dosage form selected from the group consisting of solution, external ointment, cream, foam, nourishing lotion, skin softener, perfume, facial mask, softening water, lotion, makeup base, essence, soap, liquid cleanser, bath preparation, sunscreen, sunscreen oil, suspension, emulsion, paste, gel, lotion, powder, soap, cleanser containing surfactant, oil, powder foundation, emulsion foundation, wax foundation, patch and spray, but is not limited thereto.

[0079] The cosmetic composition of the present invention may additionally contain one or more cosmetically acceptable carriers used in conventional skin cosmetics. Conventional ingredients such as oil, water, surfactants, moisturizers, lower alcohols, thickeners, chelating agents, pigments, preservatives, and fragrances may be appropriately added, but are not limited thereto.

[0080] The cosmetically acceptable carrier contained in the cosmetic composition of the present invention varies depending on the dosage form of the cosmetic composition.

[0081] When the cosmetic formulation of the present invention is in the form of an ointment, cream, or gel, the carrier component may include, but is not limited to, animal oils, vegetable oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc, zinc oxide, and the like. These may be used alone or in combination of two or more.

[0082] When the dosage form of the present invention is a solution or emulsion, a solvent, solubilizer, or emulsifier may be used as a carrier component, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, and the like, particularly cottonseed oil, peanut oil, cornseed oil, olive oil, castor oil, and sesame oil, glycerol fatty esters, polyethylene glycol, or fatty acid esters of sorbitan, but are not limited thereto. These may be used alone or in combination of two or more.

[0083] When the dosage form of the present invention is a suspension, the carrier component may include, but is not limited to, liquid diluents such as water, ethanol, or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan esters, and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacanth gum. These may be used alone or in combination of two or more.

[0084] When the dosage form of the present invention is a soap, the carrier component may include, but is not limited to, alkali metal salts of fatty acids, fatty acid half-ester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerol, sugars, and the like. These may be used alone or in combination of two or more.

[0085] When the dosage form of the present invention is a powder or spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate, polyamide powder or a mixture thereof can be used as a carrier component. In particular, when it is a spray, a propellant such as chlorofluorocarbons, propane / butane or dimethyl ether can be additionally contained.

[0086] As a specific embodiment of the present invention, a cosmetic composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Saccharomyces cerevisiae KCTC14779BP may be provided, but the present invention is not limited thereto.

[0087] As a specific embodiment of the present invention, a cosmetic composition for calming skin, regenerating skin, improving skin inflammation, moisturizing skin, improving wrinkles, improving elasticity, whitening skin, anti-oxidation, anti-aging, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus or strengthening skin barrier function can be provided, but is not limited thereto.

[0088] As a specific embodiment of the present invention, a cosmetic composition for improving wrinkles, improving elasticity, preventing aging, calming the skin, improving skin inflammation or moisturizing the skin can be provided, which contains Lactobacillus fructosus KCTC14776BP, but is not limited thereto.

[0089] As a specific embodiment of the present invention, a cosmetic composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Bacillus paramycoides KCTC14777BP may be provided, but the present invention is not limited thereto.

[0090] As a specific embodiment of the present invention, a cosmetic composition for moisturizing the skin comprising Bacillus megaterium KCTC14778BP may be provided, but the present invention is not limited thereto.

[0091] On the other hand, all the ingredients described in the present invention can preferably be included in the composition of the present invention within the range not exceeding the maximum usage values ​​specified in relevant regulations such as cosmetic safety standards and China's "Cosmetic Safety and Technical Specifications".

[0092] Another aspect of the present invention provides a quasi-drug composition for improving skin, comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the culture or fermentation product.

[0093] The above-mentioned “Saccharomyces cerevisiae”, “Lactobacillus fructosus”, “Bacillus paramycoides”, “Bacillus megaterium”, “strain”, “culture”, “fermentation product”, “fraction”, “yeast polypeptide”, “skin improvement”, “improvement”, “wrinkles”, “elasticity”, “collagen”, “aging”, “moisturizing skin”, “hyaluronic acid”, “regeneration”, “calming skin”, “inflammation” and “NO”, “whitening”, “antioxidant”, “protecting skin from external stimulation”, “anti-aging” and “sensitive skin” are as described above.

[0094] The term "quasi-drugs" of the present invention may be selected from the group consisting of shower gel, disinfectant cleaner, detergent, kitchen cleaner, cleaning cleaner, toothpaste, mouthwash, wet wipes, lotion, soap, hand soap, hair cleanser, hair softener, humidifier filler, facial mask, ointment and filter filler, but is not limited thereto.

[0095] In addition to the aforementioned ingredients, the quasi-drug composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient, or diluent, as needed. The pharmaceutically acceptable carrier, excipient, or diluent is not limited, as long as it does not impair the effects of the present invention, and may include, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, flavoring agents, preservatives, and the like.

[0096] Representative examples of pharmaceutically acceptable carriers, excipients or diluents of the present invention can include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerol, gum arabic, alginate, calcium phosphate, calcium carbonate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil, injectable esters, witepsol, macrogol, Tween 61, cocoa butter, lauryl esters, etc.

[0097] When the culture of the bacterial strain of the present invention, its fermented product or the fraction of the above-mentioned culture or fermented product is used as a medicine, it is possible to additionally contain one or more active ingredients that show the same or similar functions. For example, it is possible to include known ingredients that enhance beneficial skin bacteria, inhibit harmful skin bacteria, calm the skin, improve skin inflammation, whiten the skin, regenerate the skin, and heal wounds. If additional wrinkle improvement, skin whitening, skin problem improvement, and moisturizing skin ingredients are included, the effects of the composition of the present invention on wrinkle improvement, elasticity improvement, moisturizing the skin, preventing aging, calming the skin, regenerating the skin, and improving skin inflammation can be further improved. When adding the above-mentioned ingredients, it is possible to consider the skin safety caused by the combined use, the ease of formulation, and the stability of the active ingredients.

[0098] The quasi-pharmaceutical composition of the present invention may additionally include retinoic acid, TGF, protein derived from animal placenta, betulinic acid, and chlorella extract, which are known in the art as skin aging prevention or moisturizing ingredients; non-steroidal anti-inflammatory ingredients such as flufenamic acid, ibuprofen, benzydamine, indomethacin, prednisolone, dexamethasone, allantoin, azulene, and hydrocortisone; and one or more components selected from the group consisting of their derivatives and various plant extracts. The content of the additional ingredients may be 0.0001% to 10% by weight relative to the total weight of the composition, and the above content range can be adjusted based on conditions such as skin safety, ease of formulation of the strain of the present invention, the culture of the strain, the fermentation product, or the fraction extracted from the fermentation product of the strain.

[0099] The formulation method, dosage, application method, constituent components, etc. of the quasi-drug can be appropriately selected from conventional techniques known in the technical field.

[0100] As a specific embodiment of the present invention, a quasi-drug composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Saccharomyces cerevisiae KCTC14779BP may be provided, but is not limited thereto.

[0101] As a specific embodiment of the present invention, a pharmaceutical composition for calming skin, regenerating skin, improving skin inflammation, moisturizing skin, improving wrinkles, improving elasticity, whitening skin, anti-oxidation, anti-aging, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus or strengthening skin barrier function can be provided, but is not limited thereto.

[0102] As a specific embodiment of the present invention, a quasi-pharmaceutical composition for improving wrinkles, improving elasticity, preventing aging, calming the skin, improving skin inflammation or moisturizing the skin can be provided, which contains Lactobacillus fructosus KCTC14776BP, but is not limited thereto.

[0103] As a specific embodiment of the present invention, a quasi-drug composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Bacillus paramycoides KCTC14777BP may be provided, but the present invention is not limited thereto.

[0104] As a specific embodiment of the present invention, a quasi-drug composition for moisturizing the skin comprising Bacillus megaterium KCTC14778BP may be provided, but the present invention is not limited thereto.

[0105] Another aspect of the present invention provides a skin-improving food composition comprising any one or more of the aforementioned strain, a culture of the aforementioned strain, a fermentation product of the aforementioned strain, and a fraction of the culture or fermentation product.

[0106] The above-mentioned “Saccharomyces cerevisiae”, “Lactobacillus fructosus”, “Bacillus paramycoides”, “Bacillus megaterium”, “strain”, “culture”, “fermentation product”, “fraction”, “yeast polypeptide”, “skin improvement”, “improvement”, “wrinkles”, “elasticity”, “collagen”, “aging”, “moisturizing skin”, “hyaluronic acid”, “regeneration”, “calming skin”, “inflammation”, “NO”, “whitening”, “antioxidant”, “protecting skin from external stimulation”, “anti-aging” and “sensitive skin” are as described above.

[0107] The term "food" in the present invention includes all foods in the usual sense, such as meat, sausage, bread, chocolate, candy, snacks, biscuits, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, oral liquids, alcoholic beverages, vitamin complexes, health functional foods, etc., and is not limited thereto, as long as it can include one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP and Bacillus megaterium KCTC14778BP of the present invention, cultures of the above strains, fermentations of the above strains, and fractions of the above cultures or fermentations. In addition, the above-mentioned strain of the present invention, the culture of the above-mentioned strain, the fermentation product of the above-mentioned strain, and the fraction of the above-mentioned culture or fermentation product can be added as the main ingredient to the prepared juice, tea, jelly and fruit juice, etc., and can be prepared in the form of pills, powders, granules, doses, tablets, capsules or liquids.

[0108] The above-mentioned health function (property) food (functional food) is a term identical to food for special health use (FoSHU), and refers to a food that is processed so as to effectively show the medical or medical effect of the regulating function of the organism in addition to supplying nutrition. Here, "function (property)" refers to the regulation of nutrients on the structure and function of the human body or the obtaining of useful effects for health purposes such as physiological effects. The food of the present invention can be prepared by a method commonly used in this area. During the above-mentioned preparation, it can be prepared by adding the raw materials and ingredients usually added in this area. In addition, the dosage form of the above-mentioned food can also be prepared without restriction, as long as it is a dosage form identified as food. The food composition of the present invention can be prepared in the dosage form of various forms, and unlike ordinary medicines, it is made of food, so it has the advantages of not producing the side effects that may occur when taking medicines for a long time, and is excellent in portability. Therefore, the food of the present invention can be taken as an adjuvant for enhancing the immune enhancement effect.

[0109] The term "health food" refers to foods that have a positive effect on maintaining or enhancing health compared to regular foods, while "health supplement food" refers to foods that are intended to supplement health. Depending on the situation, the terms "health functional food," "health food," and "health supplement food" are used interchangeably.

[0110] Specifically, the above-mentioned health functional food is a food prepared by adding one or more strains selected from the group consisting of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP and Bacillus megaterium KCTC14778BP, cultures of the above-mentioned strains, fermentations of the above-mentioned strains, and fractions of the above-mentioned cultures or fermentations to food materials such as beverages, teas, spices, chewing gums, biscuits, etc., or preparing them into encapsulated, powdered, suspensions, etc., and means that when they are ingested, they will bring specific health effects, but unlike ordinary medicines, they are made from food, so they have the advantage of not producing side effects that may occur when taking medicines for a long time.

[0111] The above composition may additionally contain a physiologically acceptable carrier, and the kind of the carrier is not particularly limited and may be arbitrarily used as long as it is a carrier commonly used in the technical field.

[0112] The composition may also contain additional ingredients commonly used in food compositions to enhance smell, taste, and visual quality. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folic acid, and pantothenic acid may be included. Minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chromium (Cr) may also be included. Amino acids such as lysine, tryptophan, cysteine, and valine may also be included.

[0113] In addition, the composition may contain food additives such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and high-grade bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), colorants (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite), seasonings (MSG monosodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, sodium, etc.), flavorings (vanillin, lactones, etc.), expanders (alum, D-potassium hydrogen tartrate, etc.), fortifiers, emulsifiers, thickeners (paste), film-forming agents, glue bases, foam inhibitors, solvents, and improvers. These additives can be selected according to the type of food and used in appropriate amounts.

[0114] Any one or more in the fraction of above-mentioned yeast saccharomyces cerevisiae KCTC14779BP, yeast saccharomyces cerevisiae KCTC14780BP, lactobacillus fructose KCTC14776BP, bacillus paramycoides KCTC14777BP or bacillus megaterium KCTC14778BP bacterial strain, the culture of above-mentioned bacterial strain, the fermentation product of above-mentioned bacterial strain and above-mentioned culture or fermentation product directly add or use together with other food or food ingredients, and can suitably use according to ordinary method.The mixed amount of active ingredient can suitably be determined according to its purpose (prevention, health or therapeutic treatment). In general, when preparing food or beverage, relative to food or beverage, food compositions of the present invention can be added with the amount below 50 weight portions, particularly below 20 weight portions. Yet, when taking in for a long time with health and hygiene as purpose, can comprise the content below the above-mentioned scope, and aspect safety, without any problem, so active ingredient can also use with the amount above the above-mentioned scope.

[0115] As an example of the food composition of the present invention, it can be used as a health drink composition. In this case, like conventional beverages, it can contain various flavoring agents or natural carbohydrates as additional ingredients. The above-mentioned natural carbohydrates can be monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrin and cyclodextrin; and sugar alcohols such as xylitol, sorbitol, and erythritol. Sweeteners can include natural sweeteners such as thaumatin and stevia extract; and synthetic sweeteners such as saccharin and aspartame. The proportion of the above-mentioned natural carbohydrates per 100 mL of the composition of the present invention is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g.

[0116] In addition to the above substances, the health drink composition can also contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin, pectin salts, alginic acid, alginic salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohol or carbonating agents etc. In addition, it can contain the pulp used to prepare natural fruit juice, fruit juice beverage or vegetable beverage. These ingredients can be used alone or in combination. Although the ratio of these additives is not too important, it is generally selected within the scope of 0.01 to 0.1 weight parts per 100 weight parts of the composition of the present invention.

[0117] Specifically, relative to the total weight of the food composition, the content of any one or more of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP or Bacillus megaterium KCTC14778BP strains, cultures of the above strains, fermentations of the above strains, and fractions of the above cultures or fermentations can be 0.00001 to 100 weight %.

[0118] As a specific embodiment of the present invention, a food composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Saccharomyces cerevisiae KCTC14779BP may be provided, but is not limited thereto.

[0119] As a specific embodiment of the present invention, a food composition for calming skin, regenerating skin, improving skin inflammation, moisturizing skin, improving wrinkles, improving elasticity, whitening skin, anti-oxidation, anti-aging, calming sensitive skin, improving sensitive skin, alleviating erythema, alleviating pruritus or strengthening skin barrier function can be provided, but is not limited thereto.

[0120] As a specific embodiment of the present invention, a food composition for improving wrinkles, improving elasticity, preventing aging, calming the skin, improving skin inflammation or moisturizing the skin can be provided, which contains Lactobacillus fructosus KCTC14776BP, but is not limited thereto.

[0121] As a specific embodiment of the present invention, a food composition for improving wrinkles, improving elasticity, preventing aging, or moisturizing the skin comprising Bacillus paramycoides KCTC14777BP may be provided, but the present invention is not limited thereto.

[0122] As a specific embodiment of the present invention, a food composition for moisturizing the skin comprising Bacillus megaterium KCTC14778BP may be provided, but the present invention is not limited thereto.

[0123] Another aspect of the present invention provides a method for preparing a fermentation product, comprising the step of fermenting using a strain selected from the group consisting of Saccharomyces cerevisiae deposited with the deposition number KCTC14779BP, Saccharomyces cerevisiae deposited with the deposition number KCTC14780BP, Lactobacillus fructivorans deposited with the deposition number KCTC14776BP, Bacillus paramycoides deposited with the deposition number KCTC14777BP, and Bacillus megaterium deposited with the deposition number KCTC14778BP.

[0124] The above-mentioned “Saccharomyces cerevisiae”, “Lactobacillus fructosus”, “Bacillus paramycoides”, “Bacillus megaterium”, “strain” and “fermentation product” are as described above.

[0125] In the present invention, Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP, Lactobacillus fructovorax KCTC14776BP, Bacillus paramycoides KCTC14777BP, or Bacillus megaterium KCTC14778BP is cultured in a culture medium at 20°C to 40°C with shaking for 1 to 200 hours, and then the cells are separated by centrifugation and then ultrasonically disrupted to prepare a fermentation product, but the present invention is not limited thereto. The culture medium used in the present invention may be MRS medium, R2A medium, or LBS medium, but the type of culture medium is not limited, as long as it can culture or ferment the strain.

[0126] Another aspect of the present invention provides a fraction preparation method, comprising: a step of culturing a Saccharomyces cerevisiae strain deposited with the deposit number KCTC14780BP; and a step of separating from the culture or fermentation product of the strain using water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane.

[0127] The above-mentioned "Saccharomyces cerevisiae", "strain" and "fraction" are as described above.

[0128] Another aspect of the present invention provides a cosmetic composition for improving skin, comprising any one or more of the strain of the present invention, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product.

[0129] Another aspect of the present invention provides a quasi-drug composition for use in improving skin, comprising any one or more of the strain of the present invention, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product.

[0130] Another aspect of the present invention provides a food composition for improving skin, comprising any one or more of the strain of the present invention, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product.

[0131] The above-mentioned "strain", "culture", "fermentation", "fraction", "yeast polypeptide", "improvement of skin", and "improvement" are as described above.

[0132] Another aspect of the present invention provides a skin improvement method comprising applying or administering to an individual a composition comprising as an active ingredient any one or more of the strain of the present invention, a culture of the strain, a fermentation product of the strain, and a fraction of the culture or fermentation product.

[0133] The above-mentioned "strain", "culture", "fermentation", "fraction", "yeast polypeptide", "improvement of skin", and "improvement" are as described above.

[0134] The term "individual" in the present invention refers to all animals including humans. The above-mentioned animals can be not only humans, but also mammals such as cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, etc. that need to treat similar symptoms, but are not limited thereto.

[0135] In the present invention, the term "application" refers to all methods of bringing the composition of the present invention into contact with the skin of an individual by any suitable method, with the purpose of absorbing the composition into the interior of the skin by this method.

[0136] When the composition of the present invention is applied to the skin of an individual, it can have the effects of improving wrinkles, improving elasticity, preventing aging, moisturizing the skin, calming the skin, regenerating the skin, improving skin inflammation, whitening the skin, anti-oxidation, anti-aging, calming sensitive skin, improving sensitive skin, relieving erythema, relieving pruritus and strengthening the skin barrier function, and can include the step of applying or administering the above-mentioned composition to the individual in an effective amount to exhibit the above-mentioned effects.

[0137] In the present invention, the term "administering" refers to a general term for providing a predetermined substance to an individual by any appropriate method, and the above-mentioned administration route can be administered by any general route as long as it can reach the target skin. Specific embodiments

[0139] Hereinafter, the present invention will be described in more detail by way of examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.

[0140] Example 1. Yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP), Lactobacillus (Lactobacillus fructosus KCTC14776BP), Bacillus (Bacillus paramycoides KCTC14777BP, Bacillus megaterium KCTC14778BP) strains Separation

[0141] Novel yeast strains, namely Saccharomyces cerevisiae CF2-0w-17, CF2-0w-22, Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30, were obtained from the plant fermentation broth fermented for one year.

[0142] The yeast Saccharomyces cerevisiae strains CF2-0w-17 and CF2-0w-22 were deposited with the Korea Type Culture Collection (KCTC), a Budapest Treaty depository, on November 16, 2021, under the accession numbers KCTC14779BP and KCTC14780BP, respectively. These strains were confirmed to have the 18s rRNA base sequences of sequence numbers 1 and 2, respectively.

[0143] The above-mentioned Lactobacillus fructivorans CF2-2w-20, Bacillus paramycoides CF1-0w-14, and Bacillus megaterium CF1-w2-30 strains were deposited with the Korean Collection of Type Cultures (KCTC), a depository under the Budapest Treaty, on November 16, 2021, with the deposit numbers KCTC14776BP, KCTC14777BP, and KCTC14778BP, respectively. It was confirmed that the above-mentioned strains have the 16s rRNA base sequences of sequence numbers 3, 4, and 5, respectively.

[0144] Example 2. Preparation of Yeast, Lactobacillus, and Bacillus Fermentations and Polypeptides Extracted from Fermentations

[0145] Example 2-1. Preparation of yeast (Saccharomyces cerevisiae KCTC14779BP, KCTC14780BP) fermentation products

[0146] Saccharomyces cerevisiae strains KCTC14779BP and KCTC14780BP were inoculated into culture medium, shaken, and then centrifuged to separate the cells. The cells were suspended in purified water and then disrupted by ultrasonication to prepare fermentation products of Saccharomyces cerevisiae KCTC14779BP or KCTC14780BP. Specific conditions and composition are shown in Table 1 below.

[0147] [Table 1]

[0148]

[0149] Example 2-2. Polypeptides extracted from yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation products and fractions containing the same Preparation

[0150] The Saccharomyces cerevisiae KCTC14780BP strain was inoculated into a culture medium and cultured with shaking. The cells were separated by centrifugation, and a lysate was obtained and concentrated. The lysate was then suspended in an alcohol concentration twice that of the lysate, and then centrifuged to separate the polypeptide fraction precipitated from the lysate. This fraction contained the yeast Saccharomyces cerevisiae KCTC14780BP polypeptide of the present invention.

[0151] Example 2-3. Lactobacillus (Lactobacillus fructosus KCTC14776BP), Bacillus (Bacillus paramycoides Preparation of fermentation products of Bacillus megaterium (KCTC14777BP, Bacillus megaterium (KCTC14778P))

[0152] Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778P were inoculated into culture medium, shaken, and then centrifuged to separate the cells. The cells were suspended in purified water and then ultrasonically disrupted to produce fermented products of Lactobacillus fructosus KCTC14776BP, Bacillus paramycoides KCTC14777BP, and Bacillus megaterium KCTC14778P. Specific conditions and composition are shown in Table 2 below.

[0153] [Table 2]

[0154]

[0155] Example 3. Confirmation of the effect of yeast, lactobacillus, and bacillus fermentation products on enhancing collagen synthesis

[0156] Example 3-1. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentation product on enhancing collagen synthesis

[0157] Human dermal fibroblasts were treated with various concentrations for 48 hours. Collagen synthesis rates were measured using the procollagen type I C-peptide (PIP) EIA kit. Collagen synthesis efficiency was calculated relative to a negative control (DMEM supplemented with 0% serum).

[0158] To confirm the effect of the fermentation product of Saccharomyces cerevisiae KCTC14779BP on enhancing collagen synthesis, the collagen synthesis rates of normal cells, normal cells treated with TGF-β, treated with the fermentation product of Saccharomyces cerevisiae KCTC14779BP yeast, and treated with the fermentation product of normal yeast (Saccharomyces cerevisiae KCTC 7296) were compared (Table 3).

[0159] [Table 3]

[0160] sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10ppb) 27.55 Saccharomyces cerevisiae KCTC14779BP fermentation product (1%) 27.22 Ordinary yeast fermentation (1%) 9.81

[0161] As shown in the results of Table 3, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14779BP. The increase rate of the fermentation product of Saccharomyces cerevisiae KCTC14779BP was superior to that of the fermentation product of normal yeast prepared under the same conditions.

[0162] Example 3-2. Confirmation of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation and fractions containing yeast polypeptides Enhance the effect of collagen synthesis

[0163] The effect of enhancing collagen synthesis was confirmed by the same method as in Example 3-1. The collagen synthesis rates of normal cells, normal cells treated with TGF-β, Saccharomyces cerevisiae KCTC14780BP fermentation products, and yeast polypeptide-containing fractions were compared (Table 4).

[0164] [Table 4]

[0165] sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10ng / ml) 23.92 Fraction containing common yeast ferment (1%) 9.81 Saccharomyces cerevisiae KCTC14780BP fermentation product (1%) 16.38 Fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide (0.01%) 16.99

[0166] As shown in the results in Table 4 above, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides. In this case, the collagen synthesis rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides was superior to that of the normal yeast fermentation product prepared under the same conditions.

[0167] Example 3-3. Confirmation of Enhanced Collagen Synthesis by Lactobacillus (Lactobacillus fructosus KCTC14776BP) Fermentation Effect

[0168] The effect of enhancing collagen synthesis was confirmed by the same method as in Example 3-1. The collagen synthesis rates of normal cells, normal cells treated with TGF-β, treated with the fermentation product of Lactobacillus fructosus KCTC14776BP, and treated with the fermentation product of Lactobacillus plantarum KCTC 3108 were compared (Table 5).

[0169] [Table 5]

[0170] sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10ppb) 24.6 Lactobacillus fructosus KCTC14776BP fermentation product (0.1%) 21.77 Common Lactobacillus ferment (0.1%) 15.12

[0171] As shown in the results of Table 5 above, it was confirmed that when ordinary cells were treated with the fermentation product of Lactobacillus fructosus (KCTC14776BP), the collagen synthesis rate increased. At this time, the rate of increase of the fermentation product of Lactobacillus fructosus (KCTC14776BP) was more excellent than that of the ordinary lactobacillus fermentation product prepared under the same conditions.

[0172] Example 3-4. Confirmation of Enhanced Collagen of Bacillus (Bacillus paramycoides KCTC14777BP) Fermentation Product Synthetic effect

[0173] The effect of enhancing collagen synthesis was confirmed by the same method as in Example 3-1. The collagen synthesis rates of normal cells, normal cells treated with TGF-β, treated with a fermentation product of Bacillus paramycoides KCTC14777BP, and treated with a fermentation product of Lactobacillus megaterium KCTC 3007 were compared (Table 6).

[0174] [Table 6]

[0175] sample Collagen synthesis rate (% of control) Normal cells (negative control group) 0 Normal cells + TGF-β (positive control group, 10ppb) 20.84 Bacillus paramycoides KCTC14777BP fermentation product (0.1%) 33.41 Common Bacillus fermentation product (0.1%) 28.59

[0176] As shown in the results of Table 6, it was confirmed that the collagen synthesis rate increased when normal cells were treated with the fermentation product of Bacillus paramycoides KCTC14777BP. The increase rate was superior to that of the fermentation product of Bacillus paramycoides KCTC14777BP prepared under the same conditions.

[0177] It can be seen that the fermentation products of Saccharomyces cerevisiae KCTC14779BP, Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, Lactobacillus fructosus KCTC14776BP and / or Bacillus paramycoides KCTC14777BP of the present invention show excellent effects in improving skin wrinkles, enhancing elasticity, etc.

[0178] Example 4. Confirmation of the Effect of Yeast, Lactobacillus, and Bacillus Fermentation Products on Enhancing Hyaluronic Acid Synthesis

[0179] Example 4-1. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14779BP) fermentation product on enhancing hyaluronic acid synthesis

[0180] Human keratinocyte HaCaT cells were treated with each concentration for 72 hours. Hyaluronic acid synthesis was compared with a control group (treated with DMEM containing 0% serum) using R&D systems' Quantikine ELISA Hyaluronan, and the moisturizing ability was quantified (Table 7).

[0181] [Table 7]

[0182]

[0183] As shown in the results of Table 7, it was confirmed that the hyaluronic acid synthesis rate increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14779BP. The increase rate of the fermentation product of Saccharomyces cerevisiae KCTC14779BP was superior to that of the fermentation product of normal yeast prepared under the same conditions.

[0184] Example 4-2. Confirmation of the effect of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation product on enhancing hyaluronic acid synthesis fruit

[0185] The effect of enhancing hyaluronic acid synthesis was confirmed by the same method as in Example 4-1 (Table 8).

[0186] [Table 8]

[0187]

[0188] As shown in the results of Table 8, it was confirmed that when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP, the hyaluronic acid synthesis rate increased compared to the control group. In this case, the hyaluronic acid synthesis rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP was superior to that of the fermentation product of normal yeast prepared under the same conditions.

[0189] Example 4-3. Confirmation of enhanced hyaluronic acid synthesis by Lactobacillus (Lactobacillus fructosus KCTC14776BP) fermentation product Effect

[0190] The effect of enhancing hyaluronic acid synthesis was confirmed by the same method as in Example 4-1 (Table 9).

[0191] [Table 9]

[0192]

[0193] As shown in the results of Table 9, it was confirmed that the hyaluronic acid synthesis rate increased when normal cells were treated with the fermentation product of Lactobacillus fructosus KCTC14776BP. The increase rate of the fermentation product of Lactobacillus fructosus KCTC14776BP was superior to that of the fermentation product of normal lactobacillus prepared under the same conditions.

[0194] Example 4-3. Confirmation of Enhanced Hyaluronic Acid in Bacillus (Bacillus paramycoides KCTC14777BP) Fermentation Synthetic effect

[0195] The effect of enhancing hyaluronic acid synthesis was confirmed by the same method as in Example 4-1 (Table 10).

[0196] [Table 10]

[0197]

[0198] As shown in the results of Table 10, it was confirmed that the hyaluronic acid synthesis rate increased when normal cells were treated with the fermentation product of Bacillus paramycoides KCTC14777BP. The increase rate was superior to that of the fermentation product of Bacillus paramycoides KCTC14777BP prepared under the same conditions.

[0199] Example 4-4. Confirmation of Enhanced Hyaluronic Acid in Bacillus (Bacillus megaterium KCTC14778BP) Fermentation Product Synthetic effect

[0200] The effect of enhancing hyaluronic acid synthesis was confirmed by the same method as in Example 4-1 (Table 11).

[0201] [Table 11]

[0202]

[0203] As shown in the results of Table 11, it was confirmed that the hyaluronic acid synthesis rate increased when normal cells were treated with the fermentation product of Bacillus megaterium KCTC14780BP. In this case, the increase rate of the fermentation product of Bacillus megaterium KCTC14778BP was superior to that of the fermentation product of normal Bacillus prepared under the same conditions.

[0204] It can be seen that the fermentation product of Saccharomyces cerevisiae KCTC14779BP, the fermentation product of Saccharomyces cerevisiae KCTC14780BP, the fermentation product of Lactobacillus fructosus KCTC14776BP, the fermentation product of Bacillus paramycoides KCTC14777BP and / or the fermentation product of Bacillus megaterium KCTC14778BP of the present invention show excellent effects in improving skin wrinkles, enhancing elasticity, moisturizing, calming the skin, etc.

[0205] Example 5. Confirmation of the increase in yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation and fractions containing yeast polypeptides Strong cell activity effect

[0206] Human dermal fibroblasts were treated with the samples at various concentrations for 48 hours. Cell viability was measured using the CCK-8 kit. The cell viability of the samples was calculated relative to the negative control (DMEM supplemented with 0% serum).

[0207] In order to confirm the effect of Saccharomyces cerevisiae KCTC14780BP fermentation and yeast polypeptide-containing fractions on enhancing cell activity, the cell activity rates of normal cells, normal cells treated with FBS, treated with Saccharomyces cerevisiae KCTC14780BP fermentation, treated with normal yeast (Saccharomyces cerevisiae KCTC 7296) fermentation, and treated with fractions containing yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptides were compared (Table 12).

[0208] [Table 12]

[0209] sample Cell viability (% of control) Normal cells (negative control group) 0 Normal cells + FBS (positive control group, 5%) 17.55 Ordinary yeast fermentation (1%) No effect (-10.89) Saccharomyces cerevisiae KCTC14780BP fermentation product (1%) 20.15 Fraction containing Saccharomyces cerevisiae KCTC14780BP polypeptide (0.1%) 60.76

[0210] As shown in the results of Table 12 above, it was confirmed that when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fermentation fraction containing the yeast (Saccharomyces cerevisiae KCTC14780BP) polypeptide, the cell activity rate increased. In this case, the increase rate of the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing the yeast polypeptide was superior to that of the normal yeast fermentation product prepared under the same conditions.

[0211] It can be seen from the above that the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides of the present invention exhibit excellent effects in terms of cell activity and the like.

[0212] Example 6. Confirmation of the Skin-Calming and Inflammation-Improving Effects of Yeast and Lactobacillus Fermentation Products (Inhibition of NO Production)

[0213] Example 6-1. Confirmation of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation and fractions containing yeast polypeptides Soothes the skin and improves inflammation (inhibits NO production)

[0214] The samples were diluted to various concentrations in Raw 264.7 cells, treated with 1 μg / ml LPS, and cultured for 24 hours. The NO production inhibitory ability was evaluated using the NO quantification kit method as follows (Table 13).

[0215] NO generation inhibition ability (%) = (1-(NO generation amount when sample is added / NO generation amount when no sample is added) x 100

[0216] [Table 13]

[0217]

[0218] As shown in the results in Table 13, it was confirmed that the ability to inhibit NO production increased when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides. The increase rate in the fermentation product of Saccharomyces cerevisiae KCTC14780BP was superior to that in the fermentation product of normal yeast prepared under the same conditions.

[0219] Example 6-2. Confirmation of the soothing effect of Lactobacillus (Lactobacillus fructose KCTC14776BP) fermentation product on skin and inflammation Effect on disease (inhibition of NO production)

[0220] The effects of soothing the skin and improving inflammation were confirmed by the same method as in Example 6-1 (Table 14).

[0221] [Table 14]

[0222] sample NO production inhibition ability (% of control) Normal cells (negative control group) 0 Normal cells + L-NMMA (positive control group, 20ug / mL) 47.9 Lactobacillus fructosus KCTC14776BP fermentation product (1%) 15.1 Common Lactobacillus ferment (1%) 4.9

[0223] As shown in the results in Table 14, it was confirmed that the ability to inhibit NO production increased when normal cells were treated with the fermentation product of Lactobacillus fructosus KCTC14776BP. The increase rate of the fermentation product of Lactobacillus fructosus KCTC14776BP was superior to that of the fermentation product of normal lactobacillus prepared under the same conditions.

[0224] It can be seen that the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides and / or the fermentation product of Lactobacillus fructosus KCTC14776BP of the present invention show excellent effects in calming the skin and improving inflammation.

[0225] Example 7. Confirmation of the inhibitory activity of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation products and fractions containing yeast polypeptides Effect of inhibiting melanin expression

[0226] Samples were diluted at various concentrations in B16f10 melanocytes, treated for 72 hours, and cultured. The amount of melanin pigment present in the melanocytes was then quantified. The melanin production inhibition rate was calculated relative to the total protein content and then expressed as a percentage based on the DMSO control group (DMEM containing 0% serum, untreated group, negative control group) as 100%.

[0227] In order to determine the extent of reduction in the amount of melanin pigment in the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides, the melanin production inhibition rate of the positive control group (Arbutin 200 ppm (Lim YJ et al., 2009, Arch Pharm Res.)), the fermentation product of Saccharomyces cerevisiae KCTC14780BP, and the fraction containing yeast polypeptides was compared (Table 15).

[0228] [Table 15]

[0229]

[0230] As shown in the results of Table 15 above, it was confirmed that when normal cells were treated with the fermentation product of Saccharomyces cerevisiae (KCTC14780BP) and the fraction containing yeast polypeptide, the melanin production inhibition rate increased.

[0231] It can be seen from the above that the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptides of the present invention show excellent effects in whitening skin.

[0232] Example 8. Confirmation of the clearing of yeast (Saccharomyces cerevisiae KCTC14780BP) fermentation products and fractions containing yeast polypeptides Free radical scavenging effect

[0233] After the sample was dissolved in DMSO, an equal amount (100 μl) of a 0.15 mM DPPH solution was mixed with the sample and reacted at room temperature for 30 minutes. Thereafter, the color change of DPPH was measured at 540 nm by absorbance (A540).

[0234] In order to evaluate the free radical scavenging ability of the Saccharomyces cerevisiae KCTC14780BP fermentation product and the fraction containing yeast polypeptides, the IC50 values ​​were calculated by measuring the A540 values ​​of the positive control group (vitamin C), the Saccharomyces cerevisiae KCTC14780BP fermentation product, and the fraction containing yeast polypeptides, thereby comparing the free radical scavenging ability (Table 16).

[0235] [Table 16]

[0236] sample IC 50 (%) Positive control group (Vitamin C) 0.000606±0.00006 Saccharomyces cerevisiae KCTC14780BP fermentation product 3.476±0.337 Fractions containing the Saccharomyces cerevisiae KCTC14780BP polypeptide 0.1804±0.0174

[0237] As shown in the results of Table 16 above, when normal cells were treated with the fermentation product of Saccharomyces cerevisiae KCTC14780BP and the fraction containing yeast polypeptide, the effect of scavenging free radicals (active oxygen species) was confirmed.

[0238] It can be seen that the fermentation product of Saccharomyces cerevisiae KCTC14780BP of the present invention has excellent effects of anti-oxidation, anti-aging and protecting skin from external stimulation.

[0239] Example 9. Confirmation of the sedation sensitivity of a fraction containing yeast polypeptides of yeast (Saccharomyces cerevisiae KCTC14780BP) Skin effects

[0240] Example 9-1. Confirmation of the effect of the yeast polypeptide-containing fraction on the inhibition of erythema / itch-inducing factor (PGE2) expression fruit

[0241] Samples diluted at various concentrations and treated with UVB (11 mJ) were cultured for 24 hours in Raw 264.7 cells. The PGE2 (Prostaglandin E2) production inhibitory capacity (%) was evaluated using a PGE2 quantitative kit. Specifically, a standard curve was prepared using 4PL regression, and the UVB-induced PGE2 production effect was calculated as 100%. The PGE2 production during the treatment of the sample was then calculated relative to the amount of PGE2 produced and the numerical values ​​were determined (Table 17).

[0242] [Table 17]

[0243]

[0244] As shown in the results of Table 17 above, when normal cells were treated with the fraction containing the Saccharomyces cerevisiae KCTC14780BP polypeptide, an effect of suppressing PGE2 expression was confirmed.

[0245] It can be seen that the yeast polypeptide-containing fraction of the present invention exhibits excellent effects in alleviating skin erythema / pruritus, calming and improving sensitive skin.

[0246] Example 9-2. Confirmation of the increase in the fraction containing yeast polypeptides to strengthen the main component of the skin barrier LOR Effects of Loricrin expression

[0247] After 3 hours of treatment with TNF-α (10 pg / ml) in HaCaT cells, the samples were diluted to various concentrations, mixed with TNF-α-treated HaCaT cells, and cultured for 24 hours. The increased expression of LOR (Loricrin), a major component of the skin barrier, was quantified using qPCR (Table 18).

[0248] [Table 18]

[0249]

[0250] As shown in the results of Table 18 above, it was confirmed that LOR expression increased when normal cells were treated with the fraction containing the Saccharomyces cerevisiae KCTC14780BP polypeptide.

[0251] It can be seen that the yeast polypeptide-containing fraction of the present invention exhibits excellent effects in strengthening the skin barrier, calming and improving sensitive skin.

[0252] Example 9-3. Confirmation of the Inhibitory Effect of Yeast Polypeptide-Containing Fractions on Inflammatory Cytokines

[0253] Samples diluted at various concentrations and treated with UVB (11 mJ) were cultured in HaCaT cells for 24 hours. The expression of inflammatory cytokines (TNF-a) in sensitive skin was calculated using qPCR and the values ​​were determined (Table 19).

[0254] [Table 19]

[0255]

[0256] As shown in the results of Table 19 above, it was confirmed that when normal cells were treated with the fraction containing the Saccharomyces cerevisiae KCTC14780BP polypeptide, TNF-α expression was suppressed.

[0257] It can be seen from the above that the yeast polypeptide-containing fraction of the present invention exhibits excellent effects in calming and improving sensitive skin.

[0258] Example 9-4. Confirmation of the inhibitory activity of the yeast polypeptide-containing fraction on the skin neurogenic factor TRPV1 Effect

[0259] The samples were diluted at various concentrations and treated in HEK 293T-TRPV1 cells. Ten minutes later, the inhibitory effect on TRPV1 (Transient receptor potential vanilloid-1) activity was evaluated using a calcium influx detection assay kit (Table 20).

[0260] [Table 20]

[0261]

[0262] As shown in the results of Table 20, it was confirmed that TRPV1 activity was inhibited when normal cells were treated with the fraction containing the Saccharomyces cerevisiae KCTC14780BP polypeptide. This was confirmed to be more effective than the positive control group treated under the same conditions.

[0263] It can be seen from the above that the yeast polypeptide-containing fraction of the present invention exhibits excellent effects in reducing skin neurological irritation / pain, calming, and improving sensitive skin.

[0264] Based on the above description, those skilled in the art will appreciate that the present invention may be implemented in other specific ways without changing the technical concept or essential features of the present invention. It should be understood that the embodiments described above are illustrative and non-restrictive in all respects. The scope of the present invention is intended to include the meaning and scope of the claims described below and all variations or modifications derived therefrom, not just the detailed description above.

Claims

1. A strain, which is a Saccharomyces cerevisiae strain deposited with the deposit number KCTC14779BP.

2. A skin-improving cosmetic composition comprising any one or more of the strain according to claim 1, a crushed product of the strain, a fermented product of the strain, and a fraction containing a polypeptide in the fermented product.

3. A quasi-drug composition for improving skin, comprising any one or more of the strain according to claim 1, a crushed product of the strain, a fermented product of the strain, and a fraction containing a polypeptide in the fermented product.

4. Use of a composition for preparing a skin-improving cosmetic composition, the composition comprising at least one of the strain according to claim 1, a crushed product of the strain, a fermented product of the strain, and a fraction containing a polypeptide from the fermented product. in, The skin improvement is any one or more selected from the group consisting of improving wrinkles, moisturizing skin, improving elasticity, whitening skin, anti-oxidation, anti-aging, and calming sensitive skin.

5. Use of any one or more of the strain according to claim 1, a fermentation product of the strain, and a fraction containing a polypeptide in the fermentation product for preparing a cosmetic composition for improving skin, wherein: The skin improvement is any one or more selected from the group consisting of improving wrinkles, moisturizing skin, improving elasticity, whitening skin, anti-oxidation, anti-aging, and calming sensitive skin, or the cosmetic composition is used to enhance cell activity, inhibit NO production, promote hyaluronic acid synthesis, promote collagen synthesis, inhibit melanin expression, scavenge free radicals, inhibit prostaglandin E2 (PGE2) expression, increase loricrin (LOR) expression, inhibit TNF-a expression or inhibit TRPV1 activity.

6. Use of a composition for preparing a quasi-drug composition for improving skin, the composition comprising at least one of the strain according to claim 1, a crushed product of the strain, a fermented product of the strain, and a fraction containing a polypeptide from the fermented product. in, The skin improvement is any one or more selected from the group consisting of improving wrinkles, moisturizing skin, improving elasticity, whitening skin, anti-oxidation, anti-aging, and calming sensitive skin.

7. Use of any one or more of the strain according to claim 1, a fermentation product of the strain, and a fraction containing a polypeptide in the fermentation product for preparing a quasi-drug composition for improving skin, wherein: The skin improvement is any one or more selected from the group consisting of improving wrinkles, moisturizing skin, improving elasticity, whitening skin, anti-oxidation, anti-aging, and calming sensitive skin, or the quasi-pharmaceutical composition is used to enhance cell activity, inhibit NO production, promote hyaluronic acid synthesis, promote collagen synthesis, inhibit melanin expression, scavenge free radicals, inhibit prostaglandin E2 (PGE2) expression, increase loricrin (LOR) expression, inhibit TNF-a expression or inhibit TRPV1 activity. 8 . A food composition comprising any one or more of the strain according to claim 1 , a disrupted product of the strain, a fermented product of the strain, and a fraction containing a polypeptide in the fermented product.

9. A method for preparing a fermented product, comprising the step of fermenting using the Saccharomyces cerevisiae strain deposited with the accession number KCTC14779BP.

10. A method for preparing a fraction containing a polypeptide, comprising: The step of culturing the Saccharomyces cerevisiae strain deposited with the accession number KCTC14779BP; as well as A step of separating the fraction from the fermentation product of the strain using water, C1 to C4 alcohol, hexane, ethyl acetate, chloroform or dichloromethane.

Images